Inhibition of MicroRNA-494 reduces carotid artery atherosclerotic lesion development and increases plaque stability

Annals of Surgery

Volumn 262, Issue 5, 2015, Pages 841-848

  Wezel, Anouk ^a,b   Welten, Sabine M J ^a   Razawy, Wida ^a,b   Lagraauw, H Maxime ^b   De Vries, Margreet R ^a   Goossens, Eveline A C ^a   Boonstra, Martin C ^a   Hamming, Jaap F ^a   Kandimalla, Ekambar R ^c   Kuiper, Johan ^b   Quax, Paul H A ^a   Nossent, A Yaël ^a   Bot, Ilze ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c HYBRIDON INC   (United States)

Author keywords

atherosclerosis; microRNA 494; plaque stability; reverse target prediction

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CHEMOKINE RECEPTOR CXCR4; CHOLESTEROL; MICRORNA; MICRORNA 14Q 32; MICRORNA 155; MICRORNA 329; MICRORNA 494; MICRORNA 495; OLIGONUCLEOTIDE; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; DNA; MIRN494 MICRORNA, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY LESION; ARTICLE; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY ATHEROSCLEROTIC LESION; CAROTID ATHEROSCLEROSIS; CAROTID ENDARTERECTOMY; CHOLESTEROL BLOOD LEVEL; COLLAGEN DEGRADATION; CONTROLLED STUDY; GENE CLUSTER; GENE EXPRESSION; HUMAN; IN VITRO STUDY; MACROPHAGE; MAST CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; UPREGULATION; VASCULAR REMODELING; ANIMAL; ATHEROSCLEROSIS; BIOSYNTHESIS; CAROTID ARTERY; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; ATHEROSCLEROSIS; BLOTTING, WESTERN; CAROTID ARTERIES; DISEASE MODELS, ANIMAL; DNA; GENE EXPRESSION REGULATION; HUMANS; MALE; MICE; MICRORNAS; PLAQUE, ATHEROSCLEROTIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84954357301     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000001466     Document Type: Article

References (29)

1. Rothwell PM, Eliasziw M, Gutnikov SA, et al. Analysis of pooled data from the randomized controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet. 2003; 361: 107-116
2. Shah PK. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol. 2003; 41: 15S-22S
3. Saba L, Potters F, van der Lugt A, et al. Imaging of the fibrous cap in atherosclerotic carotid plaque. Cardiovasc Intervent Radiol. 2010; 33: 681-689
4. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol. 2009; 27: 165-197
5. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012; 32: 2045-2051
6. Chen K, Rajewsky N. The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet. 2007; 8: 93-103
7. Rajewsky N. MicroRNA target predictions in animals. Nat Genet. 2006; 38: S8-S13
8. van Rooij E, Olson EN. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov. 2012; 11: 860-872
9. Nossent AY, Eskildsen TV, Andersen LB, et al. The 14q32 microRNA-487b targets the antiapoptotic insulin receptor substrate 1 in hypertension-induced remodeling of the aorta. Ann Surg. 2013; 258: 743-753
10. Rayner KJ, Esau CC, Hussain FN, et al. Inhibition of miR-33a/b in nonhuman primates raises plasma HDL and lowers VLDL triglycerides. Nature. 2011; 478: 404-407
11. Sun C, Alkhoury K, Wang YI, et al. IRF-1 and miRNA126 modulate VCAM-1 expression in response to a high-fat meal. Circ Res. 2012; 111: 1054-1064
12. Fang Y, Davies PF. Site-specific microRNA-92a regulation of Kruppel-like factors 4 and 2 in atherosusceptible endothelium. Arterioscler Thromb Vasc Biol. 2012; 32: 979-987
13. Alaiti MA, Orasanu G, Tugal D, et al. Kruppel-like factors and vascular inflammation: implications for atherosclerosis. Curr Atheroscler Rep. 2012; 14: 438-449
14. Wang YS, Wang HY, Liao YC, et al. MicroRNA-195 regulates vascular smooth muscle cell phenotype and prevents neointimal formation. Cardiovasc Res. 2012; 95: 517-526
15. Nazari-Jahantigh M, Wei Y, Noels H, et al. MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages. J Clin Invest. 2012; 122: 4190-4202
16. Zhu J, Chen T, Yang L, et al. Regulation of microRNA-155 in atherosclerotic inflammatory responses by targeting MAP3K10. PLoS One. 2012; 7: e46551
17. Ji R, Cheng Y, Yue J, et al. MicroRNA expression signature and antisensemediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. Circ Res. 2007; 100: 1579-1588
18. Boon RA, Hergenreider E, Dimmeler S. Atheroprotective mechanisms of shear stress-regulated microRNAs. Thromb Haemost. 2012; 108: 616-620
19. Welten SM, Bastiaansen AJ, de Jong R, et al. Inhibition of 14q32 microRNAs miR-329, miR-487b, miR-494, and miR-495 increases neovascularization and blood flow recovery after ischemia. Circ Res. 2014; 115: 696-708
20. Zernecke A, Bot I, Djalali-Talab Y, et al. Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res. 2008; 102: 209-217
21. Bot I, Daissormont IT, Zernecke A, et al. CXCR4 blockade induces atherosclerosis by affecting neutrophil function. JMol Cell Cardiol. 2014; 74C: 44-52
22. Bot I, de Jager SC, Zernecke A, et al. Perivascular mast cells promote atherogenesis and induce plaque destabilization in apolipoprotein E-deficient mice. Circulation. 2007; 115: 2516-2525
23. Willems S, Vink A, Bot I, et al. Mast cells in human carotid atherosclerotic plaques are associated with intraplaque microvessel density and the occurrence of future cardiovascular events. Eur Heart J. 2013; 34: 3699-3706
24. Seitz H, Royo H, Bortolin ML, et al. A large imprinted microRNA gene cluster at the mouse Dlk1-Gtl2 domain. Genome Res. 2004; 14: 1741-1748
25. Benetatos L, Hatzimichael E, Londin E, et al. The microRNAs within the DLK1-DIO3 genomic region: involvement in disease pathogenesis. Cell Mol Life Sci. 2013; 70: 795-814
26. Aavik E, Lumivuori H, Leppänen O, et al. Global DNA methylation analysis of human atherosclerotic plaques reveals extensive genomic hypomethylation and reactivation at imprinted locus 14q32 involving induction of a miRNA cluster. Eur Heart J. 2015; 36: 993-1000
27. Mallat Z, Gojova A, Marchiol-Fournigault C, et al. Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res. 2001; 89: 930-934
28. Pei C, Barbour M, Fairlie-Clarke KJ, et al. Emerging role of interleukin-33 in autoimmune diseases. Immunology. 2014; 141: 9-17
29. Epstein SE, Stabile E, Kinnaird T, et al. Janus phenomenon: the interrelated tradeoffs inherent in therapies designed to enhance collateral formation and those designed to inhibit atherogenesis. Circulation. 2004; 109: 2826-2831